Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis

被引:124
作者
Moore, MR
Perdreau-Remington, F
Chambers, HF
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Div Infect Dis, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA
关键词
D O I
10.1128/AAC.47.4.1262-1266.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Heterogeneous resistance to vancomycin is thought to precede emergence of intermediate susceptibility to vancomycin in Staphylococcus aureus, but the clinical significance of heterogeneous resistance is unknown. Paired S. aureus isolates from a patient with endocarditis who relapsed after vancomycin treatment were tested for heterogeneous resistance to vancomycin. The pretreatment and the relapse clinical isolates (strains SF1 and SF2, respectively) were genotyped by pulsed-field gel electrophoresis. Susceptibility to vancomycin was assessed by the broth dilution method, population analysis, and time-kill studies and in the rabbit model of endocarditis. Strains SF1 and SF2 had similar genotypes, and the vancomycin MICs for the strains were less than or equal to2 mug/ml. SF2 exhibited heterogeneous resistance to vancomycin. Vancomycin eradicated SF1 in the rabbit model of endocarditis, while SF2 persisted at pretreatment levels. Vancomycin treatment failure in this patient with endocarditis was attributable to heterogeneous resistance to vancomycin.
引用
收藏
页码:1262 / 1266
页数:5
相关论文
共 24 条
[1]   METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS AT BOSTON CITY HOSPITAL - BACTERIOLOGIC AND EPIDEMIOLOGIC OBSERVATIONS [J].
BARRETT, FF ;
MCGEHEE, RF ;
FINLAND, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1968, 279 (09) :441-&
[2]   INFECTIVE ENDOCARDITIS [J].
BAYER, AS .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (03) :313-320
[3]   AMPICILLIN, SULBACTAM, AND RIFAMPIN COMBINATION TREATMENT OF EXPERIMENTAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS IN RABBITS [J].
CHAMBERS, HF ;
KARTALIJA, M ;
SANDE, M .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :897-902
[4]   STUDIES OF RP 59500 INVITRO AND IN A RABBIT MODEL OF AORTIC-VALVE ENDOCARDITIS CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
CHAMBERS, HF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 :117-122
[5]   IN NITRO AND IN-VIVO ANTISTAPHYLOCOCCAL ACTIVITIES OF L-695,256, A CARBAPENEM WITH HIGH-AFFINITY FOR THE PENICILLIN-BINDING PROTEIN PBP 2A [J].
CHAMBERS, HF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :462-466
[6]   EFFECTS OF DOSAGE, PEAK AND TROUGH CONCENTRATIONS IN SERUM, PROTEIN-BINDING, AND BACTERICIDAL RATE ON EFFICACY OF TEICOPLANIN IN A RABBIT MODEL OF ENDOCARDITIS [J].
CHAMBERS, HF ;
KENNEDY, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (04) :510-514
[7]   ENDOCARDITIS DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS IN RABBITS - EXPRESSION OF RESISTANCE TO BETA-LACTAM ANTIBIOTICS INVIVO AND INVITRO [J].
CHAMBERS, HF ;
HACKBARTH, CJ ;
DRAKE, TA ;
RUSNAK, MG ;
SANDE, MA .
JOURNAL OF INFECTIOUS DISEASES, 1984, 149 (06) :894-903
[8]   TEICOPLANIN VERSUS NAFCILLIN AND VANCOMYCIN IN THE TREATMENT OF EXPERIMENTAL ENDOCARDITIS CAUSED BY METHICILLIN-SUSCEPTIBLE OR METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
CHAMBERS, HF ;
SANDE, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (01) :61-64
[9]   Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco [J].
Charlebois, ED ;
Bangsberg, DR ;
Moss, NJ ;
Moore, MR ;
Moss, AR ;
Chambers, HF ;
Perdreau-Remington, F .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (04) :425-433
[10]   COMPARATIVE EFFICACIES OF CIPROFLOXACIN, PEFLOXACIN, AND VANCOMYCIN IN COMBINATION WITH RIFAMPIN IN A RAT MODEL OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS CHRONIC OSTEOMYELITIS [J].
DWORKIN, R ;
MODIN, G ;
KUNZ, S ;
RICH, R ;
ZAK, O ;
SANDE, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) :1014-1016